Intrauterine insemination at 42 hours versus 36 hours after the hCG ovulation trigger
Official title: Interest of Sperm Insemination at 42 Hours Post hCG Compared to 36h in Intrauterine Insemination : a Randomized Controlled Trial. SYNcIU
Run by University Hospital, Toulouse · NCT06804538 · Data updated 2026-11-12
This study will test whether doing IUI 42 hours instead of 36 hours after the hCG shot leads to more live births for people having intrauterine insemination for infertility.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 43 Years |
| Sex | Women only |
| Enrollment | 692 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 4 sites (Bordeaux and 3 other locations) |
| Status | Recruiting |
| Started | September 9, 2025 |
| Main results expected | December 1, 2028 |
| Study ends | December 1, 2028 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT06804538 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–43 with two patent fallopian tubes undergoing their first or second gonadotropin-stimulated IUI cycle with GnRH antagonist, using partner or donor sperm (prior migration test ≥1 million inseminable sperm), who meet local legal and consent requirements.
✕Probably not a fit
People with blocked tubes, severe male-factor infertility requiring IVF, those outside the age limits, or those needing treatments other than gonadotropin stimulation with GnRH antagonist are unlikely to benefit from this timing comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized superiority trial will compare timing of intrauterine insemination performed at 42–43 hours versus 36–37 hours after hCG ovulation trigger in people undergoing gonadotropin-stimulated cycles with a GnRH antagonist. Participants will receive standard ovarian stimulation, luteal phase progestin support, and insemination using partner or donor sperm according to local procedures, with only the timing of IUI differing between groups. The primary outcome is live birth rate per cycle, and centers across France will follow participants through pregnancy outcome. The trial will also record sperm origin and other cycle variables to explore whether timing effects differ by sperm source.
Why it matters
Potential benefit: If successful, delaying IUI to about 42 hours after hCG could increase the chance of a live birth per cycle by better aligning egg maturity and sperm availability.
How similar studies have gone: Previous randomized trials have reported higher pregnancy rates with delayed IUI to around 42 hours, but this is the first trial designed to measure live birth as the primary outcome.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Single unmarried woman or heterosexual or homosexual couple in which the woman wishing to carry the pregnancy is aged 18 to 43 and the spouse is aged 18 to 60 at the time of inclusion * 2 permeable tubes for the woman receiving the insemination * Spouse's sperm (Number of inseminable sperm ≥ 1 million in prior survival migration test) or sperm donation * 1st or 2nd intrauterine insemination for this child project * Ovarian stimulation by gonadotropin with GnRH antagonist (introduced on a fixed day or according to the follicular size criterion of the center) * Luteal phase support with a progestin until at least the pregnancy test * Affiliation or beneficiary of a social security scheme or equivalent for both partners of the couple if applicable * Free and informed consent signed by the unmarried woman or both members of the couple * Couples and unmarried women meeting the conditions for access to PMA according to the French bioethics law Exclusion Criteria: * Endometriosis stage III or IV * History of ectopic pregnancy * ≥ 3 spontaneous miscarriages * Single woman or couple where one of the two partners (or both) is (are) under the protection of justice, under guardianship or under curatorship * Single woman or couple who have already participated in the study once * Single woman or couple participating in another interventional clinical study
Where it's running
-
CHU Toulouse
Toulouse, France Recruiting -
CHU Bordeaux
Bordeaux, France Not yet recruiting -
CHU La Réunion
La Réunion, France Not yet recruiting -
CHU Poitiers
Poitiers, France Not yet recruiting
Study contacts
- Study coordinator: Jessika MOREAU, MD
- Email: moreau.je@chu-toulouse.fr
- Phone: 567771017
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted embryo selection on day 5 in IVF for infertility
This trial tests whether an AI-based embryo selection tool can help pick the best embryo for transfer on day 5 in IVF/ICSI to improve pregnancy chances for people with infertility.
-
Preserving sperm quality with aging through cryopreservation
This study tests whether freezing and thawing sperm can help keep younger-like DNA and molecular traits in men as they age.
-
Unstimulated Egg Retrieval with CAPA-IVM and Euploid Embryo Transfer
This study tests whether eggs can be collected without ovarian stimulation, matured in the lab, and used to create a single euploid embryo for transfer in infertility patients.
-
Ultra-Long GnRH-a Pretreatment Before Frozen Embryo Transfer for Deep Infiltrating Endometriosis
In people under 40 with deep infiltrating endometriosis and infertility, the study tests whether two injections of a GnRH agonist before hormone support improve pregnancy outcomes in their first frozen-thawed embryo transfer.
-
Endometrial Waves and Pregnancy in FET Cycles with Hormone Therapy
This study tests whether patterns of uterine contractions during hormone-prepared frozen embryo transfer affect pregnancy outcomes.
-
Environmental and lifestyle factors linked to ART success in infertility patients
This study follows 5,000 infertile men and women to see how environmental exposures and lifestyle relate to the success of assisted reproductive technology.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.